Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use HEMLIBRA safely and effectively. See full prescribing information for HEMLIBRA. HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
- generic_name
- emicizumab
- product_names
- emicizumab
- ndc
- 50242-920, 50242-921, 50242-922, 50242-923, 50242-927, 50242-930, 50242-920-01, 50242-921-01, 50242-922-01, 50242-923-01, 50242-930-01, 50242-927-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en